Bristol-Myers Squibb Aktie News

Stocking stuffers are small, inexpensive presents that help to complete the holiday, so for this screen, the focus was on inexpensive stocks. Inexpensive means a low P/E multiple relative to the S&P 500 NYSEARCA: SPY, but it doesn't mean cheap.

Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.

Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co (NYSE:BMY).  The pact is focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.

Bristol-Myers Squibb Company is down 40%, while the market is up 20%. The reason is the collapse in its growth outlook created by patent cliffs. Despite some amazing growth in new drugs, Bristol's three super mega-blockbuster patent cliffs are creating zero-growth headwinds for the foreseeable future. Even without growth, Bristol-Myers is 28% undervalued, yielding the most in 15 years, and offe...

Avidity Biosciences Inc. RNA said Tuesday it's expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal that will see Avidity receive $100 million upfront with the potential to earn up to $2.2 billion in milestone payments. The news sent Avidity's stock up 21% in premarket trade.

Although the stock market whipsawed investors over the past few years, it showed its resilience by bouncing sharply higher after the pandemic collapse. As it has for more than a century, every double-digit decline by stocks is followed by a bull market.

When bad news happens to good companies, it just might be a signal to consider buying shares. Johnson Controls has a solid business, but its stock is down thanks to less-than-ideal guidance.

Investors should consider selling stocks with negative catalysts and at risk of further decline. Taxable account holders may realize losses to offset this year's capital gains. Avoid Companies with high debt, falling demand, or higher operating losses ahead.